PBLA

NASDAQ

Panbela Therapeutics Inc.

SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations

News25/Ratings1

Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing disruptive therapeutics for the treatment of patients with cancer. The company focuses on diseases of the pancreas, including pancreatitis and pancreatic cancer. Its lead product candidate is SBP-101, which is in Phase 1a/1b clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was founded in 2011 and is based in Waconia, Minnesota.

Latest news

25 items

429dSEC
Panbela Therapeutics Inc. filed SEC Form 8-K: Leadership Update
8-K - Panbela Therapeutics, Inc. (0001029125) (Filer)
443dSEC
Panbela Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
8-K - Panbela Therapeutics, Inc. (0001029125) (Filer)
456dSEC
Panbela Therapeutics Inc. filed SEC Form 8-K: Events That Accelerate or Increase a Direct Financial Obligation, Changes in Control of Registrant
8-K - Panbela Therapeutics, Inc. (0001029125) (Filer)
468dSEC
SEC Form S-8 filed by Panbela Therapeutics Inc.
S-8 - Panbela Therapeutics, Inc. (0001029125) (Filer)
520dINSIDER
SEC Form 4 filed by Large owner Nant Capital, Llc
4 - Panbela Therapeutics, Inc. (0001029125) (Issuer)
521dSEC
SEC Form 424B3 filed by Panbela Therapeutics Inc.
424B3 - Panbela Therapeutics, Inc. (0001029125) (Filer)
521dSEC
SEC Form 424B3 filed by Panbela Therapeutics Inc.
424B3 - Panbela Therapeutics, Inc. (0001029125) (Filer)
521dSEC
SEC Form 424B3 filed by Panbela Therapeutics Inc.
424B3 - Panbela Therapeutics, Inc. (0001029125) (Filer)
521dSEC
SEC Form 424B3 filed by Panbela Therapeutics Inc.
424B3 - Panbela Therapeutics, Inc. (0001029125) (Filer)
521dSEC
SEC Form 424B3 filed by Panbela Therapeutics Inc.
424B3 - Panbela Therapeutics, Inc. (0001029125) (Filer)
521dSEC
SEC Form 424B3 filed by Panbela Therapeutics Inc.
424B3 - Panbela Therapeutics, Inc. (0001029125) (Filer)
521dSEC
SEC Form 424B3 filed by Panbela Therapeutics Inc.
424B3 - Panbela Therapeutics, Inc. (0001029125) (Filer)
521dSEC
Panbela Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Changes in Control of Registrant, Financial Statements and Exhibits
8-K - Panbela Therapeutics, Inc. (0001029125) (Filer)
524dSEC
SEC Form 424B3 filed by Panbela Therapeutics Inc.
424B3 - Panbela Therapeutics, Inc. (0001029125) (Filer)
524dSEC
SEC Form 424B3 filed by Panbela Therapeutics Inc.
424B3 - Panbela Therapeutics, Inc. (0001029125) (Filer)
524dSEC
SEC Form 424B3 filed by Panbela Therapeutics Inc.
424B3 - Panbela Therapeutics, Inc. (0001029125) (Filer)
524dSEC
SEC Form 424B3 filed by Panbela Therapeutics Inc.
424B3 - Panbela Therapeutics, Inc. (0001029125) (Filer)
524dSEC
SEC Form 424B3 filed by Panbela Therapeutics Inc.
424B3 - Panbela Therapeutics, Inc. (0001029125) (Filer)
524dSEC
SEC Form 424B3 filed by Panbela Therapeutics Inc.
424B3 - Panbela Therapeutics, Inc. (0001029125) (Filer)
524dSEC
SEC Form 424B3 filed by Panbela Therapeutics Inc.
424B3 - Panbela Therapeutics, Inc. (0001029125) (Filer)
525dSEC
SEC Form 10-Q filed by Panbela Therapeutics Inc.
10-Q - Panbela Therapeutics, Inc. (0001029125) (Filer)
525dSEC
Panbela Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
8-K - Panbela Therapeutics, Inc. (0001029125) (Filer)
525dPR
Panbela Provides Business Update and Reports Q3 2024 Financial Results
MINNEAPOLIS, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB:PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today provides a business update and reports financial results for the quarter ended September 30, 2024. As previously announced, management is hosting an earnings call today at 4:30 p.m. ET. Q3 2024 and Recent Highlights: Up to $12.0 million financing commitment secured from strategic investor, Nant Capital.First patient enrolled in a Phase I dose escalation study to evaluate CPP-1X-S (eflornithine sachets) in STK11 mutant non-small cell lung cancer (NSCLC). Jennifer K. Simpson,
539dPR
Panbela to Host Third Quarter 2024 Earnings Conference Call on November 14, 2024
MINNEAPOLIS, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB:PBLA), ("Panbela"), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it will host a conference call on November 14, 2024, at 4:30 PM Eastern Time to discuss results for its third quarter ended September 30, 2024. Conference Call InformationToll Free: 877-545-0320International: 973-528-0002Participant Access Code: 370494Webcast Link: https://www.webcaster4.com/Webcast/Page/2556/51548 Conference Call Replay InformationToll Free: 877-481-4010International: 919-882-2331Replay Passcode: 51548Webcast Replay: https://www.
541d13D/G
SEC Form SC 13D filed by Panbela Therapeutics Inc.
SC 13D - Panbela Therapeutics, Inc. (0001029125) (Subject)